Table 2.

Demographics of propranolol-treated patients

Burn PatientSexAge, yrTBSA, %Transfusions, pRBC UnitsPropranolol Dose
Patient 3M59212PBD2–4: 10 mg 3×. PBD5–6: 20 mg 3×. PBD8–11: 20 mg 1–2×. Stopped after day11.
Patient 5M292116PBD7–18: 10 mg 2–3×. PBD19–22: 10 mg 1–2×. PBD23–48: 10 mg 3–4×.
Patient 6M254623PBD2–7: 10–30 mg 1–3×. PBD8–29: 40–70 mg 2–3×. 7th week sample not available.
Patient 7M383611PBD4–7: 10 mg 3×. PBD8–10: 20 mg 2×. PBD11–12: 30 mg 3×. Stopped after day 12. 7th week sample not available.
Patient 9F3767.630PBD2–30: 10 mg 1–2×. PBD37–48: 10–30 mg 1×.
Patient 10M50216PBD2–4: 10 mg 1×. PBD9–25: 30 mg 1–3×. PBD26–29: 20 mg 1–3×. PBD30–33: 10 mg 2×.
Patient 12M26305PBD1–30: 5–30 mg 1–3×.
Patient 14M55329PBD2–4: 10–20 mg 1–2×. PBD5–9: 30–70 mg 1–2×. PBD10–28: 10–40 mg 1–2×.
PBD29–34: 40–60 mg 1–2×. PBD35–37: 8–30 mg 1–2×.
M = 7; F = 1Mean ± SE: 39.8 ± 4.7Mean ± SE: 34.3 ± 5.7Mean ± SE: 12.75 ± 3.4; Median = 10
  • Six burn patients (3, 5, 7, 9, 10, and 12) received propranolol (PR) not exceeding 30-mg single dose (range = 5–30 mg), whereas 2 patients (6 and 14) received higher than 30-mg (range = 40–70 mg) single-dose PR during the study period. 7th week sample was not available for patients 6 and 7. PBD, post burn day; ×, times per day PR administration.